A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
Razelle KurzrockDouglas W BallMarianna L ZahurakBarry D NelkinVivek SubbiahShabina AhmedAshley O'ConnorEnusha KarunsenaRose M ParkinsonJustin A BishopYoonji HaRajni SharmaChristopher D GockeRalph ZinnerMichelle A RudekSteven I ShermanNilofer S AzadPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Pazopanib + trametinib was tolerable at full single-agent doses with clinical activity in DTC but did not achieve the prespecified response rate target.